共 29 条
- [1] A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 TrialTRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (06): : 358e1 - 358e7Bashir, QaiserNishihori, TaigaPasquini, Marcelo C.Martens, Michael J.Wu, JuanAlsina, MelissaAnasetti, ClaudioBrunstein, ClaudioDawson, PeterEfebera, YvonneGasparetto, CristinaGeller, NancyGiralt, SergioHall, Aric C.Koreth, JohnMcCarthy, PhilipScott, EmmaStadtmauer, Edward A.Vesole, David H.Hari, Parameswaran
- [2] Phase I/II Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients with High Risk (HR) Multiple Myeloma (MM)BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S154 - S154Becker, Pamela S.Alsina, MelissaZhong, XiaoboHari, Parameswaran N.Rowley, ScottStadtmauer, Edward A.Vesole, DavidLogan, Brent R.Weisdorf, Daniel J.Qazilbash, MuzaffarPopplewell, LeslieNavarro, Willis H.Tomblyn, MarcieGiralt, Sergio A.Pasquini, Marcelo C.
- [3] Randomized, Double Blind, Placebo-Controlled Trial of a TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) After Allogeneic Stem Cell Transplant (SCT). A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) StudyBIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S169 - S169Yanik, GregoryHo, Vincent T.Horowitz, MaryWeisdorf, Daniel J.Logan, Brent R.Wu, JuanSoiffer, Robert J.Wingard, John R.Levine, John E.Ferrara, James L. M.Giralt, Sergio A.White, EricCarter, Shelly L.DiFronzo, NancyCooke, Kenneth R.
- [4] Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701)BLOOD, 2014, 124 (21)Laport, Ginna G.Wu, JuanLogan, Brent R.Bachanova, VeronikaHosing, Chitra M.Fenske, Timothy S.Longo, Walter L.Devine, Steven M.Nademanee, Auayporn P.Gersten, IrisHorowitz, Mary M.Lazarus, Hillard M.Riches, Marcie L.
- [5] Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT)Followed By Lenalidomide Maintenance for Multiple Myeloma (MM) with or without Vaccination with Dendritic Cell/ Myeloma Fusions (DC/MM fusion vaccine): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1401BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S62 - S63Avigan, David E.Shah, NinaLogan, BrentZhu, JiaxiBisharat, LinaCallander, Natalie S.Chodon, ThinleDhakal, BinodEfebera, Yvonne A.Geller, NancyHematti, PeimanHerman, MicheleLazarus, Hillard M.McKenna, David H., Jr.Nelson, CourtneyNooka, AjayO'Brien, KellyO'Donnell, Lynn C.Rapoport, Aaron P.Rosenblatt, JacalynSoiffer, Robert J.Stroopinsky, DinaTorka, PallawiUhl, LynneWaller, Edmund K.Wu, JuanYoung, James W.Pasquini, Marcelo C.Chung, David J.
- [6] Results of the Blood and Marrow Transplant Clinical Trials Network Study BMT CTN 0601: Scurt - a Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation (BMT) for Children with Severe Sickle Cell DiseaseBIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S104 - S104Shenoy, ShaliniEapen, MaryWu, JuanWalters, Mark C.Levine, John E.Logan, Brent R.Gersten, Iris D.Kamani, Naynesh R.
- [7] Exercise and Stress Management Training For Patients Undergoing Autologous Or Allogeneic Hematopoietic Cell Transplantation. Results From Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902BLOOD, 2013, 122 (21)Lee, Stephanie J.Le Rademacher, JenniferJim, HeatherSyrjala, Karen L.Wingard, John R.Logan, Brent R.Wu, JuanMajhail, Navneet S.Wood, William A.Rizzo, J. DouglasGeller, Nancy L.Kitko, Carrie L.Faber, Edward A., Jr.Abidi, Muneer H.Slater, Susan E.Horowitz, Mary M.Jacobsen, Paul
- [8] Posoleucel for the prevention of clinically significant infections in high-risk allogeneic hematopoietic cell transplant recipients: Design of a phase 2/3, randomized, double-blind, placebo-controlled trialBONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 280 - 281Sica, S.Besley, C.Boundy, K.Matzko, M.Tripkovic, N.Socie, G.
- [9] A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) StudyBLOOD, 2015, 126 (23)Shenoy, ShaliniEapen, MaryWu, JuanWalters, Mark C.Levine, John E.Logan, BrentGersten, Iris D.Kamani, Naynesh R.
- [10] Letermovir (LET) for prevention of cytomegalovirus (CMV) infection: results from a phase III randomized, double-blind, placebo (PBO)-controlled trial in adult allogeneic hematopoietic cell transplant (alloHCT) recipientsBONE MARROW TRANSPLANTATION, 2017, 52 : S11 - S12Ljungman, P.Marty, F. M.Chemaly, R. F.Maertens, J.Duarte, R. F.Teal, V. L.Wan, H.Kartsonis, N. A.Leavitt, R. Y.Badshah, C.